AnaptysBio (ANAB) vs Hemab Therapeutics (COAG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.42 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | COAG |
|---|---|---|
| Share price | $46.44 | $30.45 |
| Market cap | $1.39B | $1.42B |
| 1-day change | +1.72% | +6.10% |
| YTD return | +41.24% | — |
| 1-year return | +129.24% | — |
| 5-year return | +138.84% | — |
| Forward P/E | 9.16 | — |
| EPS (TTM) | $-0.96 | $-4.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $55.42 |
| 52-week low | $20.18 | $23.00 |
| Distance from 52-week high | -35.83% | -45.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +87.90% | +100.99% |
| Average volume | 563.32K | 453.97K |
| Shares outstanding | 29.90M | 46.71M |
| Employees | — | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
ANAB vs COAG FAQ
Which is bigger, AnaptysBio or Hemab Therapeutics?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.42B compared with $1.39B for AnaptysBio (ANAB).
Are AnaptysBio and Hemab Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AnaptysBio and Biotechnology: Biological Products (No Diagnostic Substances) for Hemab Therapeutics.